Detalles de la búsqueda
1.
Arginase-1-based vaccination against the tumor microenvironment: the identification of an optimal T-cell epitope.
Cancer Immunol Immunother
; 68(11): 1901-1907, 2019 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-31690955
2.
TGFß-specific T cells induced by a TGFß-derived immune modulatory vaccine both directly and indirectly modulate the phenotype of tumor-associated macrophages and fibroblasts.
J Immunother Cancer
; 12(2)2024 Feb 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-38417917
3.
Arginase-1 specific CD8+ T cells react toward malignant and regulatory myeloid cells.
Oncoimmunology
; 13(1): 2318053, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38404966
4.
An arginase1- and PD-L1-derived peptide-based vaccine for myeloproliferative neoplasms: A first-in-man clinical trial.
Front Immunol
; 14: 1117466, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36911725
5.
First in man study: Bcl-Xl_42-CAF®09b vaccines in patients with locally advanced prostate cancer.
Front Immunol
; 14: 1122977, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-36999039
6.
CCL22-based peptide vaccines induce anti-cancer immunity by modulating tumor microenvironment.
Oncoimmunology
; 11(1): 2115655, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36052217
7.
Arginase-1 targeting peptide vaccine in patients with metastatic solid tumors - A phase I trial.
Front Immunol
; 13: 1023023, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36330525
8.
TGFß-derived immune modulatory vaccine: targeting the immunosuppressive and fibrotic tumor microenvironment in a murine model of pancreatic cancer.
J Immunother Cancer
; 10(12)2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36600556
9.
Anti-PD-L1/PD-L2 therapeutic vaccination in untreated chronic lymphocytic leukemia patients with unmutated IgHV.
Front Oncol
; 12: 1023015, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-36483037
10.
Peptide vaccination activating Galectin-3-specific T cells offers a novel means to target Galectin-3-expressing cells in the tumor microenvironment.
Oncoimmunology
; 11(1): 2026020, 2022.
Artículo
en Inglés
| MEDLINE | ID: mdl-35111385
11.
Cytotoxic T cells isolated from healthy donors and cancer patients kill TGFß-expressing cancer cells in a TGFß-dependent manner.
Cell Mol Immunol
; 18(2): 415-426, 2021 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33408343
12.
Clinical efficacy of T-cell therapy after short-term BRAF-inhibitor priming in patients with checkpoint inhibitor-resistant metastatic melanoma.
J Immunother Cancer
; 9(7)2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34210820
13.
A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma.
Nat Med
; 27(12): 2212-2223, 2021 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-34887574
14.
Arginase 1-Based Immune Modulatory Vaccines Induce Anticancer Immunity and Synergize with Anti-PD-1 Checkpoint Blockade.
Cancer Immunol Res
; 9(11): 1316-1326, 2021 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-34518197
15.
An immunogenic first-in-human immune modulatory vaccine with PD-L1 and PD-L2 peptides is feasible and shows early signs of efficacy in follicular lymphoma.
Oncoimmunology
; 10(1): 1975889, 2021.
Artículo
en Inglés
| MEDLINE | ID: mdl-38283034
16.
The metabolic enzyme arginase-2 is a potential target for novel immune modulatory vaccines.
Oncoimmunology
; 9(1): 1771142, 2020 06 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-32923127
17.
Peptide Vaccination Against PD-L1 With IO103 a Novel Immune Modulatory Vaccine in Multiple Myeloma: A Phase I First-in-Human Trial.
Front Immunol
; 11: 595035, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-33240282
18.
High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.
Blood Cancer J
; 9(2): 8, 2019 01 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-30655510
19.
MERTK Acts as a Costimulatory Receptor on Human CD8+ T Cells.
Cancer Immunol Res
; 7(9): 1472-1484, 2019 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-31266785
20.
Spontaneous T-cell responses against Arginase-1 in the chronic myeloproliferative neoplasms relative to disease stage and type of driver mutation.
Oncoimmunology
; 7(9): e1468957, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-30228936